Bone Therapeutics Restates Priorities
Bone Therapeutics will not pursue U.S. clinical development of PREOB® autologous cell therapy. In the U.S., priority will be given to the development of ALLOB®, with clinical programs to be developed during 2017. Nov 08, 2016